Nemolizumab Sustains Atopic Dermatitis Response at 3 Years
Three-year extension data show nemolizumab sustains response in adults with moderate-to-severe atopic dermatitis, according to commentary from Matthias Augustin, MD, in HCPLive.
Topic
Pruritus
Topic
Pruritus
Nemluvio Delivers Sustained Improvement in Moderate-to-Severe Atopic Dermatitis
Galderma reports Nemluvio (nemolizumab) delivered sustained improvements in moderate-to-severe atopic dermatitis, reinforcing the…
Multi-Specific Biologics Take Aim at the Eczema Efficacy Gap
A Frontiers review maps 18 bispecific and trispecific antibodies for atopic dermatitis after registry data showed ~85% of biologi…
Nemolizumab Shows Sustained Atopic Dermatitis Benefit to Three Years
Galderma reports at EADV 2026 that nemolizumab (Nemluvio) delivered sustained improvements in moderate-to-severe atopic dermatiti…
Nemolizumab Shows Sustained Response up to Three Years in Atopic Dermatitis
Long-term data report sustained nemolizumab response in moderate-to-severe atopic dermatitis patients treated for up to three yea…
Rare Skin Cancer Presents as an Itchy Rash, Not a Tumor
A rare skin cancer hides behind one of dermatology's most common complaints — itch — The Washington Post reports, with a rash-lik…